药王千金黄芩网

您所在的位置:首页 > 药市资讯 > 对抗慢性丙型肝炎的直接抗病毒药物中药物相互作用的临床意义

对抗慢性丙型肝炎的直接抗病毒药物中药物相互作用的临床意义

发布时间:2014/1/26 14:09:08点击率:473

  此文章来源于www.yws86.com

  The clinical significance of drug–drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C

  B. Maasoumy, K. Port, B. Calle Serrano, A. A. Markova, L. Sollik, M. P. Manns, M. Cornberg, H. Wedemeyer

  Background

  Drug–drug interactions (DDIs) in the treatment of chronic hepatitis C infection became a potential challenge with the introduction of direct-acting anti-virals (DAAs). Both currently approved DAAs, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), are substrates and inhibitors of P-glycoprotein and the cytochrome P450 3A4, which are regularly involved in DDIs.

  Aim

  To analyse the risk for DDIs in patients with chronic HCV genotype 1 infection considered for PI treatment at a tertiary referral centre.

  Methods

  The first 115 consecutive patients selected for a PI therapy at Hannover Medical School were included. All changes to co-medication before and during PI treatment were documented. Drugs were checked for DDIs with TVR and BOC using DDI websites and the respective prescribing information.

  Results

  Out-patient medication contained 116 different drugs. Median number of drugs/patient was 2 (range 0–11). The risk for DDIs was substantial for 38% of the drugs affecting 49% of patients. Only 4% of the drugs were strictly contraindicated. DDIs between a PI and drugs newly prescribed during anti-viral therapy were considerable in 42% of the patients. Suspected DDIs were managed by dose adjustments and discontinuation of co-medication in 7% and 21% of the patients respectively.

  Conclusions

  Many patients with chronic HCV genotype 1 infection are affected by potential DDIs if treated with a protease inhibitor, but only in a minority of cases co-medication is strictly incompatible. Overall, the challenge of DDIs is time-consuming, but well manageable by a careful review of the patient's drug chart and monitoring during treatment.

  Alimentary Pharmacology & Therapeutics

     更多资讯来自药王千金黄芩网

相关链接

最新资讯

更多>>

千金药方

更多>>
网站名称:药王千金黄芩网  [管理入口]
杨凌农交所 提供云服务技术支持
药王千金黄芩网 © 版权所有 联 系 人:王经理 固定电话:18691858474
电子邮箱:laoniuhh@126.com 详细地址:陕西省铜川市耀州区药王山孙思邈故里